13F HOLDINGS REPORT
Patient Square Capital LP
Quarter ended Q3 2024 · Filed November 14, 2024 · Accession 0000950123-24-011804
Total Value
$269.4M
Positions
11
Other Managers
0
Confidential Omitted
No
Holdings (11)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | ROIVANT SCIENCES LTD | ROIV | 12,228,465 | $141.1M | 52.38% |
| 2 | LIQUIDIA CORPORATION | LQDA | 7,182,532 | $71.8M | 26.66% |
| 3 | CULLINAN THERAPEUTICS, INC. | CGEM | 824,705 | $13.8M | 5.12% |
| 4 | INSMED INC | INSM | 171,704 | $12.5M | 4.65% |
| 5 | EYEPOINT PHARMACEUTICALS | EYPT | 1,361,979 | $10.9M | 4.04% |
| 6 | NURIX THERAPEUTICS, INC. | NRIX | 325,789 | $7.3M | 2.72% |
| 7 | PHARVARIS N.V. | PHVS | 242,341 | $4.5M | 1.67% |
| 8 | INTELLIA THERAPEUTICS, INC. | NTLA | 128,569 | $2.6M | 0.98% |
| 9 | ENLIVEN THERAPEUTICS, INC. | ELVN | 90,572 | $2.3M | 0.86% |
| 10 | OCULAR THERAPEUTIX, INC. | OCUL | 235,498 | $2.0M | 0.76% |
| 11 | ASTRIA THERAPEUTICS, INC. | 04635X102 | 39,422 | $434,036 | 0.16% |